Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHORAL Flow Study
2018-002483-11Phase 4Unknown
- Sponsor
- Imperial College London
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of evolocumab in coronary arteriosclerosis and hypercholesterolemia, sponsored by Imperial College London. Primary endpoint: Maximal coronary flow velocity. Status: unknown.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on 2018-002483-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002483-11.